Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Sentinel lymph node in melanoma].

T Meyer1, M Möhrle, C Garbe

  • 1Klinik und Poliklinik der Universität Erlangen-Nürnberg, Erlangen. thomas.meyer@chir.imed.uni-erlangen.de

Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen
|July 28, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Early switch from run-in with targeted to immunotherapy in advanced BRAF<sup>V600</sup>-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial.

ESMO open·2025
Same author

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology.

European journal of cancer (Oxford, England : 1990)·2024
Same author

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Sentinel node biopsy (SNB) is a key advance in malignant melanoma staging, replacing prophylactic dissection. SNB identifies patients needing further lymph node dissection, as sentinel node metastasis impacts prognosis.

Area of Science:

  • Oncology
  • Surgical Pathology

Background:

  • Sentinel node biopsy (SNB) has become crucial for staging malignant melanoma.
  • It replaces traditional elective lymph node dissection for primary melanoma with suspected metastasis.

Purpose of the Study:

  • To evaluate the role of SNB in melanoma staging and patient selection for further treatment.
  • To assess the prognostic significance of sentinel node metastasis.

Main Methods:

  • SNB procedure for identifying and analyzing the sentinel lymph node in melanoma patients.
  • Statistical analysis of sentinel node status as a prognostic factor.

Main Results:

  • SNB allows selection of patients (12-25%) with metastatic involvement for regional lymph node dissection.

Related Experiment Videos

  • Sentinel node metastasis is a significant independent prognostic factor in melanoma.

    • Conclusions:

    • SNB is a valuable tool for accurate melanoma staging and guiding treatment decisions.
    • The prognostic impact of sentinel node metastasis is confirmed, but further research is needed on advanced detection methods and therapeutic benefits.